Terminated NA INTERVENTIONAL 2-arm NCT05259514

CytoSorb SAH Trial

The Efficacy of CytoSorb in the Removal of IL-6 in Severe Aneurysmal Subarachnoid Hemorrhage - a Two Phase Study - a Primary Feasibility Study (Phase 1) - a Secondary Randomized, Controlled, Prospective Proof-of-concept Study (Phase 2)

Sponsor: CytoSorbents Europe GmbH

Conditions Aneurysmal Subarachnoid Haemorrhage

Interventions CytoSorb

Updated 6 times since 2022 Last updated: Aug 3, 2022 Started: Jan 31, 2022 Primary completion: Jun 16, 2022 Completion: Jun 16, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

safety

Other terminated trials from CytoSorbents Europe GmbH

Acute Coronary Syndrome · Phase NA · Dec 2021

More terminations from CytoSorbents Europe GmbH

A NA clinical study on Aneurysmal Subarachnoid Haemorrhage, this trial is terminated or withdrawn. The trial is conducted by CytoSorbents Europe GmbH and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated NA
Sep 2024 — Sep 2025 [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Sep 2022 — Jul 2024 [monthly]

Terminated NA
Jul 2022 — Sep 2022 [monthly]

Terminated NA

Status: Recruiting → Terminated

▶ Show 1 earlier version

Mar 2022 — Jul 2022 [monthly]

Recruiting NA

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CytoSorbents Europe GmbH
Emanuela Keller

Data source: University of Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland